Thrombocytopenia & Acute Coagulation Disorders
Comprehensive emergency medicine management of acute thrombocytopenia, microangiopathic hemolytic anemias, consumptive coagulopathies, and congenital bleeding disorders: emergent diagnostic differentiation of TTP versus ITP and HIT, PLASMIC score stratification, emergent Plasma Exchange (PEX) indications, strict platelet transfusion contraindications, DIC cryoprecipitate and FFP resuscitation, and precise Factor VIII and Factor IX replacement formulas for hemophilia crises.
Resuscitation Quick Actions • First 2 Minutes
TTP Platelet Ban
NEVER transfuse platelets in suspected TTP or HIT unless catastrophic exsanguination or intracranial hemorrhage is occurring (transfusion accelerates fatal microvascular thrombosis)
TTP Emergent Therapy
Stat Hematology consult for Plasma Exchange (PEX/plasmapheresis) + Methylprednisolone 1 g IV (or Prednisone 1 mg/kg) + Caplacizumab (anti-vWF nanobody)
ITP Transfusion Threshold
Platelets < 20,000-30,000/mcL WITH bleeding OR < 10,000/mcL asymptomatic -> Dexamethasone 40 mg PO/IV daily x 4 days PLUS IVIG 1 g/kg IV
Hemophilia A Factor Dosing
Severe life-threatening bleed (ICH, airway, retroperitoneal): Target 100% factor activity -> Recombinant Factor VIII: Weight (kg) x 50 IU/kg IV
Hemophilia B Factor Dosing
Severe life-threatening bleed: Target 100% factor activity -> Recombinant Factor IX: Weight (kg) x 100 IU/kg IV
DIC Fibrinogen Target
Fibrinogen < 150 mg/dL in active hemorrhage -> Administer 10-20 units Cryoprecipitate (10 units raises fibrinogen by ~50-70 mg/dL)
Bottom-Line Clinical Pearl
In any patient presenting with thrombocytopenia and microangiopathic hemolytic anemia (schistocytes on peripheral smear), presumptively diagnose Thrombotic Thrombocytopenic Purpura (TTP) and order emergent Plasma Exchange (PEX). Platelet transfusions are STRICTLY CONTRAINDICATED in TTP and Heparin-Induced Thrombocytopenia (HIT); giving platelets 'fuels the fire' of systemic microvascular thrombosis, precipitating fatal myocardial infarction, stroke, or mesenteric ischemia.
Acute thrombocytopenia in the emergency department ranges from benign incidental laboratory anomalies to fulminant, fatal thrombotic microangiopathies. The immediate emergency priorities are to rule out pseudothrombocytopenia (in vitro EDTA-dependent platelet clumping confirmed by examining a peripheral blood smear or repeating the CBC in a sodium citrate tube), assess for active mucosal or intracranial bleeding, and distinguish consumptive thrombotic microangiopathies from immune-mediated destruction.
| Platelet Count Range | Clinical Bleeding Risk | ED Resuscitation & Diagnostic Priorities |
|---|---|---|
| > 50,000/mcL | Generally asymptomatic; surgical bleeding may be prolonged, but spontaneous hemorrhage is rare. | Perform routine diagnostic evaluation (medication review, liver enzymes, coagulation profile, viral serologies). Outpatient hematology follow-up if hemodynamically stable without trauma. |
| 20,000 to 50,000/mcL | Post-traumatic bleeding; easy bruising, petechiae, and ecchymoses following minor blunt trauma. | Assess for mucosal bleeding. Avoid IM injections, NSAIDs, and antiplatelet drugs. Transfuse only for active major hemorrhage or invasive emergent procedures (target >= 50,000/mcL for lumbar puncture or major surgery). |
| 10,000 to 20,000/mcL | High risk for spontaneous purpura, epistaxis, gingival bleeding, menorrhagia, and hematuria. | Identify etiology (ITP vs drug-induced vs marrow infiltration). Initiate immunosuppression for ITP (corticosteroids). Admit symptomatic patients or those with mucosal wet purpura. |
| < 10,000/mcL | EXTREME RISK for catastrophic spontaneous hemorrhage: intracranial hemorrhage (ICH), fatal gastrointestinal bleeding, and massive retroperitoneal bleeding. | Immediate bed rest, fall precautions, strict avoidance of arterial punctures or nasogastric tubes. Non-contrast head CT for any headache or altered mental status. Prepare emergent medical therapy (IVIG + steroids) and rule out TTP before ordering platelet transfusions. |
| Disorder & Pathophysiology | Diagnostic Triad/Scoring Criteria | Emergency Pharmacotherapy & Interventions |
|---|---|---|
| Thrombotic Thrombocytopenic Purpura (TTP) Severe deficiency of ADAMTS13 metalloproteinase (autoantibodies or congenital) leads to ultralarge von Willebrand factor (vWF) multimers that anchor to endothelium, causing extensive microvascular platelet thrombosis and mechanical RBC shear. | Classic 'FAT RN' Pentad (only 20-30% exhibit all 5!): 1. Fever 2. Anemia (MAHA with prominent schistocytes, elevated LDH, indirect hyperbilirubinemia, low haptoglobin) 3. Thrombocytopenia (profound, usually < 30k) 4. Renal insufficiency (usually mild) 5. Neurologic symptoms (fluctuating confusion, focal deficits, seizures, coma) PLASMIC Score >= 6 indicates high probability of severe ADAMTS13 deficiency (< 10%). | STAT HEMATOLOGY CONSULTATION & ICU ADMISSION: 1. Plasma Exchange (PEX/Plasmapheresis): 1.0 to 1.5 plasma volumes exchanged daily with donor FFP (removes anti-ADAMTS13 antibodies and ultralarge multimers; replenishes ADAMTS13). If PEX is delayed, infuse FFP (30 mL/kg/day) as a temporizing bridge. 2. Methylprednisolone 1 g IV daily (or Prednisone 1 mg/kg PO). 3. Caplacizumab (Cablivi) 10 mg IV load, then 10 mg SC daily (anti-vWF nanobody preventing platelet aggregation). 4. ABSOLUTE CONTRAINDICATION: Platelet transfusion! Platelets 'add fuel to the fire', causing widespread microvascular thrombosis, acute MI, stroke, and arrest. |
| Immune Thrombocytopenic Purpura (ITP) Acquired autoimmune destruction of circulating platelets mediated by anti-GpIIb/IIIa IgG autoantibodies, coupled with impaired megakaryocyte thrombopoiesis. | Diagnosis of Exclusion: - Severe isolated thrombocytopenia with completely NORMAL peripheral blood smear (no schistocytes, normal RBC and WBC morphology) - Normal coagulation profile (PT, aPTT, fibrinogen normal) - Absence of splenomegaly, systemic infection, or lymphadenopathy. | Treatment Indications: - Platelets < 30,000/mcL with active bleeding OR - Platelets < 20,000/mcL asymptomatic. First-Line Regimens: 1. Dexamethasone 40 mg PO/IV daily for 4 days OR Prednisone 1 mg/kg PO daily for 1-2 weeks. 2. IVIG (Intravenous Immunoglobulin): 1 g/kg IV daily for 1-2 days (blocks splenic Fc receptors; achieves faster platelet rise within 24-48 hours, preferred for active bleeding). 3. Platelet Transfusions: Ineffective under standard conditions due to antibody clearance. Reserve ONLY for life-threatening exsanguination or ICH, administered simultaneously with high-dose IVIG. |
| Heparin-Induced Thrombocytopenia (HIT) Type II HIT is an immune-mediated reaction: IgG autoantibodies form against PF4-Heparin complexes, cross-linking platelet FcγRIIa receptors and triggering intense platelet activation, consumption, and paradoxical venous/arterial thrombosis. | 4Ts Clinical Scoring System: 1. Thrombocytopenia (> 50% drop from baseline, nadir 20k-100k) 2. Timing (day 5 to 10 of heparin exposure; or < 24h if re-exposed within 100 days) 3. Thrombosis (new DVT, PE, arterial limb ischemia, or skin necrosis at injection site) 4. oTher causes excluded. Score 6-8: High risk (> 50% chance of HIT). | IMMEDIATE ACTIONS: 1. DISCONTINUE ALL HEPARIN PRODUCTS: Stop unfractionated heparin, LMWH, heparin flushes, and coated vascular catheters. 2. Start Alternative Non-Heparin Anticoagulant (even in the absence of documented thrombosis): - Argatroban IV infusion (direct thrombin inhibitor, titrate to aPTT 1.5-3x baseline; hepatic clearance) OR - Bivalirudin IV infusion (renal clearance) OR - Fondaparinux (factor Xa inhibitor, SC dosing). 3. DO NOT GIVE WARFARIN during acute phase (depletion of Protein C causes catastrophic venous limb gangrene and skin necrosis). Reverse warfarin with Vitamin K if already given. 4. DO NOT TRANSFUSE PLATELETS (fuels thrombosis). |
DIC is an acquired systemic thrombohemorrhagic syndrome characterized by uncontrolled, widespread activation of intravascular coagulation. Massive generation of thrombin produces microvascular fibrin deposition, tissue ischemia, and multi-organ failure, while simultaneous relentless consumption of platelets and clotting factors causes profound bleeding diathesis.
| Trigger/Etiology | Laboratory Biomarker Profile | Targeted Component Resuscitation |
|---|---|---|
| Underlying Triggers: - Severe Sepsis/Septic Shock (Gram-negative endotoxemia) - Massive Trauma & Crush Injury - Obstetric Catastrophes (Amniotic fluid embolism, Placental abruption) - Acute Promyelocytic Leukemia (APL) & Malignancy - Severe Burns & Snake Envenomation. | 1. Platelet Count: Marked drop (< 50,000/mcL) 2. Coagulation Times: Markedly prolonged PT/INR and aPTT 3. Fibrinogen: Critically depleted (< 100-150 mg/dL) 4. Fibrin Degradation Products (FDP) & D-Dimer: Skyrocketed (> 10-20x upper limit of normal) 5. Peripheral Blood Smear: Schistocytes and fragmented erythrocytes (microangiopathic shearing). | Three-Pronged Management: 1. Treat the Primary Etiology: Broad-spectrum antimicrobials and source control for sepsis; emergent delivery for obstetric abruption; operative hemorrhage control for trauma. 2. Cryoprecipitate: First-line for severe hypofibrinogenemia. Administer 10 to 20 units IV to achieve a target serum fibrinogen > 150 mg/dL (10 units raises fibrinogen by 50-70 mg/dL in a 70-kg adult). 3. Fresh Frozen Plasma (FFP): 15 to 30 mL/kg IV to correct prolonged PT/INR (> 1.5) and aPTT. 4. Platelet Transfusion: Maintain platelets > 50,000/mcL in active bleeding, or > 20,000/mcL if high risk of hemorrhage. |
Hemophilia A (Factor VIII deficiency) and Hemophilia B (Factor IX deficiency/Christmas disease) are X-linked recessive bleeding disorders. Patients presenting to the ED with acute trauma, suspected intracranial hemorrhage, deep muscle hematomas (iliopsoas), or hemarthroses require IMMEDIATE factor replacement prior to sending patients for imaging studies.
| Clinical Scenario | Target Factor Activity Level | Hemophilia A (Factor VIII) Dose Formula | Hemophilia B (Factor IX) Dose Formula |
|---|---|---|---|
| Life-Threatening/Major Hemorrhage: - Intracranial/CNS Hemorrhage - Retroperitoneal or Iliopsoas Bleed - Retropharyngeal/Airway Hematoma - Major Trauma or Emergent Surgery | 100% Target Activity (1.0 IU/mL) | Formula: Weight (kg) x Target % Rise x 0.5 Dose = Weight (kg) x 50 IU/kg IV (1 unit/kg of Factor VIII raises plasma activity by 2%). Repeat infusion: 25 IU/kg every 8-12 hours. | Formula: Weight (kg) x Target % Rise x 1.0 Dose = Weight (kg) x 100 IU/kg IV (1 unit/kg of Factor IX raises plasma activity by 1%). Repeat infusion: 50 IU/kg every 12-24 hours. |
| Moderate Hemorrhage: - Acute Hemarthrosis (knee, elbow, ankle) - Significant soft-tissue hematoma - Dental extraction bleeding | 50% Target Activity (0.5 IU/mL) | Dose = Weight (kg) x 25 IU/kg IV Repeat every 12-24 hours until joint mobility and pain resolve. | Dose = Weight (kg) x 50 IU/kg IV Repeat every 24 hours until pain and effusion resolve. |
| Alternative Products When Concentrates Unavailable | Emergency temporary bridge when recombinant or plasma-derived factor is delayed: | Cryoprecipitate: Rich in Factor VIII, vWF, and fibrinogen. 1 bag contains ~80-100 IU of Factor VIII. (FFP is inadequate due to volume overload). | 4-Factor Prothrombin Complex Concentrate (4F-PCC) or FFP: Contains Factor IX. 4F-PCC can deliver 25-50 IU/kg of Factor IX rapidly without volume overload. |
The Platelet Transfusion Paradox in TTP and HIT
Platelet transfusions in patients with suspected Thrombotic Thrombocytopenic Purpura (TTP) or Heparin-Induced Thrombocytopenia (HIT) are STRICTLY CONTRAINDICATED. In both pathologies, the fundamental mechanism is not bone marrow failure or simple destruction, but systemic platelet hyperactivation and microvascular thrombosis. Infusing donor platelets into a circulation rich in ultralarge vWF multimers (TTP) or PF4-heparin-IgG complexes (HIT) delivers fresh substrate directly to the thrombotic cascade, a phenomenon known clinically as 'throwing kerosene on a burning fire'. This precipitates immediate, extensive microvascular occlusion, producing catastrophic acute myocardial infarction, ischemic stroke, mesenteric ischemia, and cardiac arrest. Platelet transfusions in TTP and HIT are permitted ONLY in cases of confirmed life-threatening intracranial hemorrhage or catastrophic exsanguinating surgical bleeding where death is immediately imminent without mechanical clotting.
Test Your Thrombocytopenia & Acute Coagulation Disorders Clinical Acumen
Directly launch an active-recall practice block from our 8,400+ validated COMLEX Level 1, 2-CE & 3 board question bank with complete explanations.
Related Emergency Protocols & Differentials
Transfusion Medicine & Coagulopathy Reversal
Massive transfusion protocols, TEG/ROTEM, and DOAC reversal.
Open Protocol Related EM ProtocolOncologic Emergencies & Tumor Lysis
Febrile neutropenia, cord compression, and hyperleukocytosis.
Open Protocol Related EM ProtocolSickle Cell Disease & Acute Crises
Vaso-occlusive bone crisis and acute chest syndrome.
Open Protocol